Clinical trial
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
NCT00106288 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00106288 |
|---|---|
| Title | Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia |
| Official title | A Multicenter, Double Blind, Comparative, Randomized Study to Evaluate the Efficacy and Safety of Micafungin (FK463) Versus Liposomal Amphotericin B (AmBisome) in the Treatment of Invasive Candidiasis and Candidemia |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Candidiasis |
| Intervention type | Drug |
| Interventions | Micafungin, Liposomal Amphotericin B |
| Enrollment | 637 |
| Start date | Jan 1, 2003 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Mar 23, 2005 |
| Last update posted | Sep 18, 2014 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: